祖细胞
干细胞
造血
内皮干细胞
生物
细胞生物学
血管生成
免疫学
内皮祖细胞
髓样
癌症研究
造血干细胞
体外
遗传学
作者
Mervin C. Yoder,Laura E. Mead,Daniel N. Prater,Theresa R. Krier,Karim N. Mroueh,Fang Li,Rachel Krasich,Constance J. Temm,Josef T. Prchal,David A. Ingram
出处
期刊:Blood
[American Society of Hematology]
日期:2006-10-19
卷期号:109 (5): 1801-1809
被引量:1372
标识
DOI:10.1182/blood-2006-08-043471
摘要
Abstract The limited vessel-forming capacity of infused endothelial progenitor cells (EPCs) into patients with cardiovascular dysfunction may be related to a misunderstanding of the biologic potential of the cells. EPCs are generally identified by cell surface antigen expression or counting in a commercially available kit that identifies “endothelial cell colony-forming units” (CFU-ECs). However, the origin, proliferative potential, and differentiation capacity of CFU-ECs is controversial. In contrast, other EPCs with blood vessel-forming ability, termed endothelial colony-forming cells (ECFCs), have been isolated from human peripheral blood. We compared the function of CFU-ECs and ECFCs and determined that CFU-ECs are derived from the hematopoietic system using progenitor assays, and analysis of donor cells from polycythemia vera patients harboring a Janus kinase 2 V617F mutation in hematopoietic stem cell clones. Further, CFU-ECs possess myeloid progenitor cell activity, differentiate into phagocytic macrophages, and fail to form perfused vessels in vivo. In contrast, ECFCs are clonally distinct from CFU-ECs, display robust proliferative potential, and form perfused vessels in vivo. Thus, these studies establish that CFU-ECs are not EPCs and the role of these cells in angiogenesis must be re-examined prior to further clinical trials, whereas ECFCs may serve as a potential therapy for vascular regeneration.
科研通智能强力驱动
Strongly Powered by AbleSci AI